134 research outputs found

    Using Argo Floats to Characterize Altimetry Products: A Study of Eddy-Induced Subsurface Oxygen Anomalies in the Black Sea

    Full text link
    peer reviewedThe identification of mesoscale eddies from remote sensing altimetry is often used as a first step for downstream analyses of surface or subsurface auxiliary data sets, in a so-called composite analysis framework. This framework aims at characterizing the mean perturbations induced by eddies on oceanic variables, by merging the local anomalies of multiple data instances according to their relative position to eddies. Here, we evaluate different altimetry data sets derived for the Black Sea and compare their adequacy to characterize subsurface oxygen and salinity signatures induced by cyclonic and anticyclonic eddies. In particular, we propose that the theoretical consistency and estimated error of the reconstructed mean anomaly may serve to qualify the accuracy of gridded altimetry products and that BGC-Argo data provide a strong asset in that regard. The most recent of these data sets, prepared with a coastal concern in the frame of the ESA EO4SIBS project, provides statistics of eddy properties that, in comparison with earlier products, are closer to model simulations, in particular for coastal anticyclones. More importantly, the subsurface signature of eddies reconstructed from BGC-Argo floats data is more consistent when the EO4SIBS data set is used to relocate the profiles into an eddy-centric coordinate system. Besides, we reveal intense subsurface oxygen anomalies which stress the importance of mesoscale contribution to Black Sea oxygen dynamics and support the hypothesis that this contribution extends beyond transport and involves net biogeochemical processes

    Monitoring Black Sea environmental changes from space: New products for altimetry, ocean colour and salinity. Potentialities and requirements for a dedicated in-situ observing system

    Get PDF
    21 pages, 13 figures, 2 tables, supplementary material https://www.frontiersin.org/articles/10.3389/fmars.2022.998970/full#supplementary-material.-- Data availability statement: The datasets generated for this study can be found on the web interface (http://www.eo4sibs.uliege.be/) and on Zenodo under data doi: 10.5281/zenodo.6397223 with a full documentation that include Products User Manuals (PUM) and Algorithm Theoretical Basis Document (ATBD). All these products are distributed in netCDF files Grégoire et al. (2022). SMOS SSS and CDM products are also available at https://bec.icm.csic.es/bec-ftp-service/In this paper, satellite products developed during the Earth Observation for Science and Innovation in the Black Sea (EO4SIBS) ESA project are presented. Ocean colour, sea level anomaly and sea surface salinity datasets are produced for the last decade and validated with regional in-situ observations. New data processing is tested to appropriately tackle the Black Sea’s particular configuration and geophysical characteristics. For altimetry, the full rate (20Hz) altimeter measurements from Cryosat-2 and Sentinel-3A are processed to deliver a 5Hz along-track product. This product is combined with existing 1Hz product to produce gridded datasets for the sea level anomaly, mean dynamic topography, geostrophic currents. This new set of altimetry gridded products offers a better definition of the main Black Sea current, a more accurate reconstruction and characterization of eddies structure, in particular, in coastal areas, and improves the observable wavelength by a factor of 1.6. The EO4SIBS sea surface salinity from SMOS is the first satellite product for salinity in the Black Sea. Specific data treatments are applied to remedy the issue of land-sea and radio frequency interference contamination and to adapt the dielectric constant model to the low salinity and cold waters of the Black Sea. The quality of the SMOS products is assessed and shows a significant improvement from Level-2 to Level -3 and Level-4 products. Level-4 products accuracy is 0.4-0.6 psu, a comparable value to that in the Mediterranean Sea. On average SMOS sea surface salinity is lower than salinity measured by Argo floats, with a larger error in the eastern basin. The adequacy of SMOS SSS to reproduce the spatial characteristics of the Black Sea surface salinity and, in particular, plume patterns is analyzed. For ocean colour, chlorophyll-a, turbidity and suspended particulate materials are proposed using regional calibrated algorithms and satellite data provided by OLCI sensor onboard Sentinel-3 mission. The seasonal cycle of ocean colour products is described and a water classification scheme is proposed. The development of these three types of products has suffered from important in-situ data gaps that hinder a sound calibration of the algorithms and a proper assessment of the datasets quality. We propose recommendations for improving the in-situ observing system that will support the development of satellite productsThis work has been carried out as part of the European Space Agency contract Earth Observation data For Science and Innovations in the Black Sea (EO4SIBS, ESA contract n° 4000127237/19/I-EF). MG received fundings from the Copernicus Marine Service (CMEMS), the European Union’s Horizon 2020 BRIDGE-BS project under grant agreement No. 101000240 and by the Project CE2COAST funded by ANR(FR), BELSPO (BE), FCT (PT), IZM (LV), MI (IE), MIUR (IT), Rannis (IS), and RCN (NO) through the 2019 “Joint Transnational Call on Next Generation Climate Science in Europe for Oceans” initiated by JPI Climate and JPI Oceans. The research on SMOS SSS has been also supported in part by the Spanish R&D project INTERACT (PID2020-114623RB-C31), which is funded by MCIN/AEI/10.13039/501100011033, funding from the Spanish government through the “Severo Ochoa Centre of Excellence” accreditation (CEX2019-000928-S) and the CSIC Thematic Interdisciplinary Platform TeledetectPeer reviewe

    Clinical practice guidelines for BRCA1 and BRCA2 genetic testing

    Get PDF
    BRCA1 and BRCA2 gene pathogenic variants account for most hereditary breast cancer and are increasingly used to determine eligibility for PARP inhibitor (PARPi) therapy of BRCA-related cancer. Because issues of BRCA testing in clinical practice now overlap with both preventive and therapeutic management, updated and comprehensive practice guidelines for BRCA genotyping are needed. The integrative recommendations for BRCA testing presented here aim to (1) identify individuals who may benefit from genetic counselling and risk-reducing strategies; (2) update germline and tumour-testing indications for PARPi-approved therapies; (3) provide testing recommendations for personalised management of early and metastatic breast cancer; and (4) address the issues of rapid process and tumour analysis. An international group of experts, including geneticists, medical and surgical oncologists, pathologists, ethicists and patient representatives, was commissioned by the French Society of Predictive and Personalised Medicine (SFMPP). The group followed a methodology based on specific formal guidelines development, including (1) evaluating the likelihood of BRCAm from a combined systematic review of the literature, risk assessment models and expert quotations, and (2) therapeutic values of BRCAm status for PARPi therapy in BRCA-related cancer and for management of early and advanced breast cancer. These international guidelines may help clinicians comprehensively update and standardise BRCA testing practices

    Autoantibodies against type I IFNs in patients with critical influenza pneumonia

    Full text link
    In an international cohort of 279 patients with hypoxemic influenza pneumonia, we identified 13 patients (4.6%) with autoantibodies neutralizing IFN-alpha and/or -omega, which were previously reported to underlie 15% cases of life-threatening COVID-19 pneumonia and one third of severe adverse reactions to live-attenuated yellow fever vaccine. Autoantibodies neutralizing type I interferons (IFNs) can underlie critical COVID-19 pneumonia and yellow fever vaccine disease. We report here on 13 patients harboring autoantibodies neutralizing IFN-alpha 2 alone (five patients) or with IFN-omega (eight patients) from a cohort of 279 patients (4.7%) aged 6-73 yr with critical influenza pneumonia. Nine and four patients had antibodies neutralizing high and low concentrations, respectively, of IFN-alpha 2, and six and two patients had antibodies neutralizing high and low concentrations, respectively, of IFN-omega. The patients' autoantibodies increased influenza A virus replication in both A549 cells and reconstituted human airway epithelia. The prevalence of these antibodies was significantly higher than that in the general population for patients 70 yr of age (3.1 vs. 4.4%, P = 0.68). The risk of critical influenza was highest in patients with antibodies neutralizing high concentrations of both IFN-alpha 2 and IFN-omega (OR = 11.7, P = 1.3 x 10(-5)), especially those <70 yr old (OR = 139.9, P = 3.1 x 10(-10)). We also identified 10 patients in additional influenza patient cohorts. Autoantibodies neutralizing type I IFNs account for similar to 5% of cases of life-threatening influenza pneumonia in patients <70 yr old

    ENIGMA-anxiety working group : Rationale for and organization of large-scale neuroimaging studies of anxiety disorders

    Get PDF
    Altres ajuts: Anxiety Disorders Research Network European College of Neuropsychopharmacology; Claude Leon Postdoctoral Fellowship; Deutsche Forschungsgemeinschaft (DFG, German Research Foundation, 44541416-TRR58); EU7th Frame Work Marie Curie Actions International Staff Exchange Scheme grant 'European and South African Research Network in Anxiety Disorders' (EUSARNAD); Geestkracht programme of the Netherlands Organization for Health Research and Development (ZonMw, 10-000-1002); Intramural Research Training Award (IRTA) program within the National Institute of Mental Health under the Intramural Research Program (NIMH-IRP, MH002781); National Institute of Mental Health under the Intramural Research Program (NIMH-IRP, ZIA-MH-002782); SA Medical Research Council; U.S. National Institutes of Health grants (P01 AG026572, P01 AG055367, P41 EB015922, R01 AG060610, R56 AG058854, RF1 AG051710, U54 EB020403).Anxiety disorders are highly prevalent and disabling but seem particularly tractable to investigation with translational neuroscience methodologies. Neuroimaging has informed our understanding of the neurobiology of anxiety disorders, but research has been limited by small sample sizes and low statistical power, as well as heterogenous imaging methodology. The ENIGMA-Anxiety Working Group has brought together researchers from around the world, in a harmonized and coordinated effort to address these challenges and generate more robust and reproducible findings. This paper elaborates on the concepts and methods informing the work of the working group to date, and describes the initial approach of the four subgroups studying generalized anxiety disorder, panic disorder, social anxiety disorder, and specific phobia. At present, the ENIGMA-Anxiety database contains information about more than 100 unique samples, from 16 countries and 59 institutes. Future directions include examining additional imaging modalities, integrating imaging and genetic data, and collaborating with other ENIGMA working groups. The ENIGMA consortium creates synergy at the intersection of global mental health and clinical neuroscience, and the ENIGMA-Anxiety Working Group extends the promise of this approach to neuroimaging research on anxiety disorders

    Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

    Full text link
    Life-threatening `breakthrough' cases of critical COVID-19 are attributed to poor or waning antibody response to the SARS- CoV-2 vaccine in individuals already at risk. Pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs underlie at least 15% of critical COVID-19 pneumonia cases in unvaccinated individuals; however, their contribution to hypoxemic breakthrough cases in vaccinated people remains unknown. Here, we studied a cohort of 48 individuals ( age 20-86 years) who received 2 doses of an mRNA vaccine and developed a breakthrough infection with hypoxemic COVID-19 pneumonia 2 weeks to 4 months later. Antibody levels to the vaccine, neutralization of the virus, and auto- Abs to type I IFNs were measured in the plasma. Forty-two individuals had no known deficiency of B cell immunity and a normal antibody response to the vaccine. Among them, ten (24%) had auto-Abs neutralizing type I IFNs (aged 43-86 years). Eight of these ten patients had auto-Abs neutralizing both IFN-a2 and IFN-., while two neutralized IFN-omega only. No patient neutralized IFN-ss. Seven neutralized 10 ng/mL of type I IFNs, and three 100 pg/mL only. Seven patients neutralized SARS-CoV-2 D614G and the Delta variant (B.1.617.2) efficiently, while one patient neutralized Delta slightly less efficiently. Two of the three patients neutralizing only 100 pg/mL of type I IFNs neutralized both D61G and Delta less efficiently. Despite two mRNA vaccine inoculations and the presence of circulating antibodies capable of neutralizing SARS-CoV-2, auto-Abs neutralizing type I IFNs may underlie a significant proportion of hypoxemic COVID-19 pneumonia cases, highlighting the importance of this particularly vulnerable population

    An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers

    Get PDF
    Introduction: Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondrial genome variations affect electron transport chain efficiency and reactive oxygen species production. Individuals with different mitochondrial haplogroups differ in their metabolism and sensitivity to oxidative stress. Variability in mitochondrial genetic background can alter reactive oxygen species production, leading to cancer risk. In the present study, we tested the hypothesis that mitochondrial haplogroups modify breast cancer risk in BRCA1/2 mutation carriers. Methods: We genotyped 22,214 (11,421 affected, 10,793 unaffected) mutation carriers belonging to the Consortium of Investigators of Modifiers of BRCA1/2 for 129 mitochondrial polymorphisms using the iCOGS array. Haplogroup inference and association detection were performed using a phylogenetic approach. ALTree was applied to explore the reference mitochondrial evolutionary tree and detect subclades enriched in affected or unaffected individuals. Results: We discovered that subclade T1a1 was depleted in affected BRCA2 mutation carriers compared with the rest of clade T (hazard ratio (HR) = 0.55; 95% confidence interval (CI), 0.34 to 0.88; P = 0.01). Compared with the most frequent haplogroup in the general population (that is, H and T clades), the T1a1 haplogroup has a HR of 0.62 (95% CI, 0.40 to 0.95; P = 0.03). We also identified three potential susceptibility loci, including G13708A/rs28359178, which has demonstrated an inverse association with familial breast cancer risk. Conclusions: This study illustrates how original approaches such as the phylogeny-based method we used can empower classical molecular epidemiological studies aimed at identifying association or risk modification effects.Peer reviewe
    corecore